Group 1 - The core point of the article is that GF Fund Management Co., Ltd. has announced an adjustment in the valuation of certain funds under its management, effective from August 22, 2025 [1] - The adjustment will apply to the stock "Huahong Company" (stock code: 688347), which will be valued using the index yield method [1] - For ETF-linked funds holding the relevant ETFs, the valuation will consider the impact of the stock valuation adjustment on the net asset value of the ETFs on the adjustment date [1]

Group 1 - The announcement from Zhongyou Chuangye Fund Management Co., Ltd. indicates a valuation adjustment for the stock of Huahong Company (stock code: 688347) held by its funds [1] - Starting from August 22, 2025, the company will adopt the "index income method" for the valuation of Huahong Company stock [1] - Once the stock resumes trading and demonstrates active market trading characteristics, the company will revert to market price valuation without further announcements [1]

Group 1 - The core point of the article is that Minsheng Jia Yin Fund Management Co., Ltd. announced an adjustment in the valuation method for its funds, specifically for the stock of China Shenhua Energy Company Limited, effective from August 7, 2025 [1] - The company will use the "index income method" for valuing the stock until it resumes trading and shows active market trading characteristics, at which point it will revert to market price valuation without further announcement [1] - As of the second quarter of 2025, Minsheng Jia Yin only holds 189,600 shares of China Shenhua through its Minsheng Jia Yin CSI Mainland Resource Theme Index Securities Investment Fund A [1]

Group 1 - The core point of the announcement is that Guotou Ruijin Fund Management Co., Ltd. will adjust the valuation of its funds based on the AMAC industry index starting from August 7, 2025, specifically for the suspended stock China Shenhua (code: 601088) using the "index income method" [1] - The adjustment is in accordance with the guidelines from the China Securities Regulatory Commission regarding the valuation of securities investment funds [1] - The company will revert to market price valuation once the stock resumes trading and demonstrates active market trading characteristics, without further announcements [1] Group 2 - According to China Shenhua's A-share Q2 2025 report, Guotou Ruijin has two funds holding the stock: Guotou Ruijin CSI Upstream Resource Industry Index Securities Investment Fund (LOF) A with 326,400 shares and Guotou Ruijin CSI Hong Kong Stock Connect Central State-Owned Enterprise Dividend Index Fund A with 9,000 shares [1]

Core Viewpoint - The valuation of NuoHui Health has been drastically reduced by multiple public funds, with Da Cheng Fund setting the latest valuation at HKD 0.55 per share, marking the lowest valuation to date [2][3][4]. Group 1: Valuation Adjustments - Da Cheng Fund announced a new valuation of HKD 0.55 per share for NuoHui Health, effective from July 31, 2025, following a series of previous adjustments [3][4]. - The valuation of NuoHui Health has been cut from HKD 14.14 per share before its suspension to HKD 0.55, representing a decline of over 96% [4]. - Other public funds, including Baoying, Penghua, and Bosera, have also significantly reduced their valuations of NuoHui Health, with Bosera valuing it at HKD 3.33 per share [4][6]. Group 2: Background and Context - NuoHui Health was once a leading stock in the Hong Kong market, known for cancer screening, with a market capitalization exceeding HKD 40 billion [6]. - The company has been suspended since March 2024 due to allegations of financial fraud and audit concerns raised by Deloitte [6][7]. - The inability to timely disclose financial reports has led to ongoing valuation adjustments by various fund companies since mid-2023 [6]. Group 3: Industry Insights - The continuous downward adjustment of NuoHui Health's valuation reflects a generally pessimistic outlook on its prospects for resuming trading and heightened market vigilance regarding potential risks [7]. - Fund managers adjust valuations to ensure the fair value of fund net assets and protect investor interests, especially when market prices do not accurately reflect intrinsic value [5][7]. - The actions taken by fund companies indicate a trend towards improved risk monitoring and control within the industry [8][9].

Core Viewpoint - The valuation of Nohow Health has been significantly reduced by multiple public funds, with Dachen Fund recently announcing a valuation of HKD 0.55 per share, marking the lowest valuation to date [1][3]. Valuation Adjustments - Dachen Fund's valuation of Nohow Health has been adjusted multiple times since its suspension in March 2024, dropping from HKD 14.14 per share to HKD 0.55 per share, representing a decline of over 96% [3][5]. - Other public funds, including Baoying, Penghua, and Bosera, have also reduced their valuations of Nohow Health, with Bosera maintaining a valuation of HKD 3.33 per share, which is still above HKD 2 per share [3][6]. Market Context - Nohow Health was once a leading stock in the Hong Kong market for cancer screening, with a market capitalization exceeding HKD 40 billion [5]. - The company has faced scrutiny over financial fraud allegations, leading to its suspension and inability to disclose timely financial reports [5][6]. Fund Management Perspective - The adjustments in valuation by fund managers aim to ensure the fairness and accuracy of fund net values, protecting investor interests [4][5]. - Continuous downward adjustments reflect a pessimistic outlook on Nohow Health's prospects for resumption of trading and heightened market vigilance regarding potential risks [6].

Core Viewpoint - The article discusses the immediate impact of financial misconduct on the valuation of Nuotai Bio, highlighting a significant downward adjustment by investment funds following the company's resumption of trading under "ST" status due to financial fraud allegations [2][4]. Group 1: Valuation Adjustments - On July 22, 2023,招商基金 announced a valuation adjustment for Nuotai Bio's stock to 32.78 yuan, representing a 20% decrease from the pre-suspension price of 40.98 yuan [6]. - As of the end of Q2 2023, a total of 8 fund companies held 19 funds that collectively owned 9.2338 million shares of Nuotai Bio, which was a reduction of 5.2611 million shares compared to the previous quarter [6]. Group 2: Financial Misconduct - The China Securities Regulatory Commission (CSRC) issued a notice on July 18, 2023, detailing two violations by Nuotai Bio: false reporting in the 2021 annual report and significant misrepresentation in public offering documents [8]. - The company falsely recognized 30 million yuan in revenue from a technology transfer to Zhejiang Huabei, which lacked the financial capability to pay for the transaction, leading to an inflated profit of 25.9516 million yuan, accounting for 20.64% of the reported total profit [8]. - Nuotai Bio was fined 47.4 million yuan, with its actual controller and several executives also facing penalties totaling 14.8 million yuan [9].